UK's MHRA consults on new fee charges
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is consulting on its proposals to change the levels of fees charged for the regulation of medicines from 1 April 2008.
The MHRA is required, as a Government Trading Fund, to recover the costs of its regulatory functions through fee income. Fee levels are revised on an annual basis, subject to consultation and Parliamentary approval.
It should be noted that the Agency has been extremely transparent about its fees proposals for 2008/2009. Included in the consultation letter, which can be viewed on the MHRA's web site (www.mhra.gov.uk), is a graphic showing its estimated expenditure budget in all areas of medicines regulation and the funding sources.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze